Category: Stents
Stents
Johnson & Johnson isn't the only party appealing a Delaware judge's ruling that four of its patents are invalid, as Boston Scientific Corp. cross-appeals despite winning the case's last round.
Boston Scientific Corp. (NYSE:BSX) may have won the most recent round in its stent patents war with Johnson & Johnson (NYSE:JNJ), but that didn't stop the Natick, Mass.-based devices giant from cross-appealing a Delaware judge's ruling.
The patents in question are at the heart of complicated legal wrangling involving Boston Scientific, its New Brunswick, N.J.-based rival and competitor/partner Abbott (NYSE:ABT). The dispute centers around Boston Scientific's Promus stent, a private-label version of Abbott's Xience V stent, and the JNJ subsidiary Cordis Corp.'s Cypher.
Sales increase 13 percent and net income jumps to $1.3 million during the fourth quarter for Burlington, Mass.-based vascular device maker LeMaitre Vascular Inc.
LeMaitre Vascular Inc. (NSDQ:LMAT) ended 2009 swinging from red to black, riding strong sales in its vascular division to positive top- and bottom-line growth for the year.
The Burlington, Mass.-based peripheral vascular device maker posted sales of $13.6 million during the three months ended Dec. 31, 2009, up 13 percent compared with the $12 million in sales the company reported during the same period in 2008.
The increased sales helped the company boost its bottom line to $1.3 million, compared to a $312,000 profit for Q4 2008.
Former U.S. Sen. Warren Rudman and Walt Disney Co. chairman John Pepper say they won't stand for re-election at the 2010 annual meeting of Natick, Mass.-based medical device giant Boston Scientific Corp.
Boston Scientific Corp. (NYSE:BSX) said two of its current board members have decided not to seek re-election for their seats at the company's next annual meeting and will be retiring from their service to the company.
Former Sen. Warren Rudman, a board member at Boston Scientific for the past 11 years, and John Pepper, who has served on and off since 1999, will both retire following the expiration of their terms, the company announced.
Rudman, who came on board at the Natick, Mass.-based medical device giant in 1999, served two terms as senator for New Hampshire from 1980-1992. He is 79 years old and sits on the board of several funds managed by the Dreyfus Corp.
A Baltimore-area physician and the hospital where he worked were slapped with a class action lawsuit after notifying nearly 370 patients that they may have been implanted with coronary stents they didn't need.
A doctor at St. Joseph Medical Center in Towson, Md., and the hospital are defendants in a class action lawsuit accusing them of implanting unnecessary coronary stents in 369 patients.
The hospital's cardiology business is already under federal investigation over the procedures, which came to light after St. Joseph's sent letters to the patients informing them that their stent implantations might not have been needed.
Researchers Sanket Dhruva and Rita Redberg on the hornet's nest they stirred up with their study of the Food & Drug Administration's approval process for high-risk cardiovascular devices.
It's not often that a few doctors ensconced in the ivy towers of academia can get a lumbering dinosaur like the Food & Drug Administration to turn on a dime, let alone during the week between Christmas and the new year.
But that's exactly what University of California at San Francisco researchers Sanket S. Dhruva, Lisa Bero and Rita Redberg did after the Journal of the American Medical Assn. published their paper "Strength of Study Evidence Examined by the FDA in Premarket Approval of Cardiovascular Devices."
Medtronics Inc. names Martin Rothman vice president of medical affairs for its coronary and peripheral vascular business.
Medtronic Inc. (NYSE:MDT) tapped veteran British interventional cardiologist Martin Rothman to lead a portion of its vascular business.
The Minneapolis medical device monolith said Rothman will be vice president of medical affairs for its Santa Rosa, Calif.-based coronary and peripheral vascular business, effective Jan. 4. He spent the last 37 years in clinical practice at the London Chest Hospital, where he directed cardiac research and development for the past 10 years.
The U.S. Supreme Court's refusal sends the case back to trial courts for damages awards in the long fight over stent patents.
The U.S. Supreme Court has declined to weigh in on a dispute between Boston Scientific Corp. and the Cordis unit of Johnson & Johnson, effectively allowing a pair of trial-court juries to determine damages in the companies' long fight over stent designs.
The nation's high court without comment Monday denied bids by the companies to review a March 31 ruling by a three-judge federal appeals panel that mostly upheld separate 2005 jury decisions that both companies had infringed on the other's patents. The appeal judges also kicked back any decisions on damages to the trial courts.
